August 2023

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 3-year Results from the Open-Label Extension of the Randomised Controlled Phase 3 SELECT-PsA 2 Study

Clin Exp Rheumatol. 2023;41(11):2286–2297 doi: 10.55563/clinexprheumatol/8l7bbk.

Data from this open-label extension showed the efficacy of upadacitinib observed at 56 weeks was maintained through to 152 weeks in the treatment of patients with PsA. No cumulative adverse effects were observed, and no new safety signals were identified.

Keywords:

Do Fatty Lesions Explain the Effect of Inflammation on New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis? Results From the SIAS Cohort and ASSERT Trial

RMD Open. 2023 9(3):e003118 doi: 10.1136/rmdopen-2023-003118

This study concluded that, in r-axSpA, vertebral corner inflammation may lead to syndesmophyte formation but in a minority of cases via visible fat deposition. Here, investigators aimed to determine how much of the effect of vertebral corner inflammation on the development of syndesmophytes is explained by vertebral corner fat deposition.

Keywords:

June 2023

Two‑Year Imaging Outcomes from a Phase 3 Randomized Trial of Secukinumab in Patients with Non‑Radiographic Axial Spondyloarthritis

Arthritis Res Ther. 2023;16;25(1):80 doi 10.1186/s13075-023-03051-5

Braun et al. studied a large cohort of patients with nr-axSpA, that demonstrated a secukinumab reduced SI joint inflammation (BME), this reduction was sustained over 104 weeks, from an overall low baseline level of spinal inflammation or structural damage.

Keywords:

May 2023

Secukinumab Improves Physical Function and Quality of Life and Inhibits Structural Damage in Patients with PsA with Sustained Remission or Low Disease Activity: Results From the 2-year Phase 3 FUTURE 5 Study

RMD Open 2023;9:e002939 doi 10.1136/rmdopen-2022-002939

Results from the 2-year phase 3 study FUTURE 5 show that the majority of patients with PsA who are treated with secukinumab were able to achieve sustained low disease activity or remission by week 104.

Keywords:

April 2023

Sex Differences in the Efficacy, Safety and Persistence of Patients with Psoriatic Arthritis Treated with Tofacitinib: A Post Hoc Analysis of Phase 3 Trials and Long-Term Extension

RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718

Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.

Keywords:

March 2023

Gender-specific Differences in Patients with Psoriatic Arthritis Receiving Ustekinumab or Tumour Necrosis Factor Inhibitor: Real-world Data

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead089

These real-world data from PsABio on gender differences suggest that, at the start of biologic treatment, females have a worse clinical picture of PsA than males. In coming to these conclusions and others, this study sought to investigate effects of gender on disease characteristics and treatment impact in patients with PsA.

Keywords:

Association Between Baseline Cardiovascular Risk and Incidence Rates of Major Adverse Cardiovascular Events and Malignancies in Patients with Psoriatic Arthritis and Psoriasis Receiving Tofacitinib

Ther Adv Musculoskelet Dis. 2023 doi: 10.1177/1759720X221149965

Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.

Keywords:

February 2023

Efficacy and Safety of Bimekizumab in Axial Spondyloarthritis: Results of Two Parallel Phase 3 Randomised Controlled Trials

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

The Effect of Guselkumab on Inhibiting Radiographic Progression in Patients with Active Psoriatic Arthritis: Study Protocol for APEX, a Phase 3b, Multicenter, Randomized, Double‑blind, Placebo‑controlled Trial

Trials. 2023 doi: 10.1186/s13063-022-06945-y

Guselkumab was approved for treating the signs and symptoms of active PsA following two Phase 3 global studies, DISCOVER-1 and DISCOVER-2. The Phase 3b APEX study has been designed to address the limitations of DISCOVER-2 and further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.

Keywords: